Appendix B: Clinical Literature Search Procedure
The literature search identified infliximab and comparator trials simultaneously, as per the NICE technology appraisal of etanercept and efalizumab. The data from this search informed the infliximab efficacy review and the indirect comparison analysis.

Medline and Embase formed the foundation of the search. These databases were combined and de-duplicated and paper selection was carried out on this combined database. The Cochrane library was also searched, but the retrieved records from this database were not systematically excluded; rather they were manually cross-checked against the results of the Medline and Embase search to ensure that no RCTs had been missed.

The figure on page 17 of the submission was intended to show how papers relating to infliximab trials only were excluded, as required out in the STA procedure manual. However since the main literature search was carried out using combined literature databases for three drugs simultaneously this figure had to be derived by hand calculation. The following should be noted about this figure:

a) The numbers of papers written against each database include comparator medications
b) All numbers except those of papers finally selected include duplicates

A detailed breakdown of the paper selection procedure is set out below together with a list of excluded and included papers at each step.

Breakdown of Medline/Embase Search Strategy
Total Medline Records: 334
Total Embase Records: 936

Total Medline/Embase Duplicates identified electronically: 339
Medline/Embase Combined: 1112

Further Duplicates identified Manually (n=24)


Excluded Non-English Papers (n=141)


**Excluded Conference Papers (n=63)**


Tayton-Martin, H. "Resurgent, refocused and on the threshold insights from Ernst & Young’s 11th annual global biotechnology reports." Journal.


Excluded Short Surveys (n=18)


Review papers Scanned for new RCTs (n=2)

Excluded Reviews

Not Adult Plaque Psoriasis Therapy (n=257)


Psoriasis therapy not involving licensed infliximab, etanercept or efalizumab (n=64)


Not RCT efficacy evidence (n=84)


Included Journal Articles

**Infliximab (n=4)**


**Etanercept (n=4)**


Efalizumab (n=4)


**NOTE TO REVIEWER:** The indirect comparison analysis in Schering-Plough submission section 5.6 used data from the above efalizumab RCT.

The analysis updated a previous analysis, at which time the Dubertret 2006 RCT was unpublished and referred to by its conference abstract which is as follows:


At the time of submission, due to an oversight the submission’s reference to Papp (2005a) was not corrected to its published equivalent nor was the correct, published reference listed in the Appendix.


**Excluded Journal Articles**

**Not Adult Plaque Psoriasis (n=266)**


Not an efficacy RCT involving licensed infliximab, etanercept or efalizumab (n=168)


### Reviews or Papers referring to Already-Identified RCTs (n=13)


